References:
1. Daniels NF, Ridwan R. Acute kidney injury precipitating myocardial
injury in a young male with COVID-19. Intern Med J. 2021;51(5):816-817.
https://doi.org/https://doi.org/10.1111/imj.14977
2. Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury
revisited: pathophysiology, prevention and future therapies. Curr Opin
Crit Care. 2014;20(6):588-595.
https://doi.org/10.1097/MCC.0000000000000153
3. de Pablo R, Monserrat J, Prieto A, Alvarez-Mon M. Role of circulating
lymphocytes in patients with sepsis. Biomed Res Int. 2014;2014(671087.
https://doi.org/10.1155/2014/671087
4. Smyth SS, Reis ED, Zhang W, et al. Beta(3)-integrin-deficient mice
but not P-selectin-deficient mice develop intimal hyperplasia after
vascular injury: correlation with leukocyte recruitment to adherent
platelets 1 hour after injury. Circulation. 2001;103(20):2501-2507.
https://doi.org/10.1161/01.cir.103.20.2501
5. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils,
and platelets cooperate to initiate and propagate venous thrombosis in
mice in vivo. J Exp Med. 2012;209(4):819-835.
https://doi.org/10.1084/jem.20112322
6. McFadyen JD, Stevens H, Peter K. The Emerging Threat of
(Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ
Res. 2020;127(4):571-587.
https://doi.org/doi:10.1161/CIRCRESAHA.120.317447
7. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19:
immunity, inflammation and intervention. Nat Rev Immunol.
2020;20(6):363-374. https://doi.org/10.1038/s41577-020-0311-8
8. Reusch N, De Domenico E, Bonaguro L, et al. Neutrophils in COVID-19.
Front Immunol. 2021;12(952).
https://doi.org/10.3389/fimmu.2021.652470
9. Liao M, Liu Y, Yuan J, et al. Single-cell landscape of
bronchoalveolar immune cells in patients with COVID-19. Nat Med.
2020;26(6):842-844. https://doi.org/10.1038/s41591-020-0901-9
10. Hermann R, Siegmund W, Giessmann T, et al. The oral, once-daily
phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic
interactions with inhaled budesonide. J Clin Pharmacol.
2007;47(8):1005-1013. https://doi.org/10.1177/0091270007300950
11. Salvesen ØNU, Davidsen JR, Pottegård A, Henriksen DP. Roflumilast
Usage from 2010 to 2016: A Danish Nationwide Drug Utilization Study.
Basic Clin Pharmacol Toxicol. 2018;123(3):314-319.
https://doi.org/https://doi.org/10.1111/bcpt.13014
12. Bonato JM, Meyer E, de Mendonça PSB, et al. Roflumilast protects
against spatial memory impairments and exerts anti-inflammatory effects
after transient global cerebral ischemia. Eur J Neurosci.
2021;53(4):1171-1188. https://doi.org/10.1111/ejn.15089
13. Kwak HJ, Song JS, Heo JY, et al. Roflumilast inhibits
lipopolysaccharide-induced inflammatory mediators via suppression of
nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun
NH2-terminal kinase activation. J Pharmacol Exp Ther.
2005;315(3):1188-1195. https://doi.org/10.1124/jpet.105.092056
14. Cortijo J, Iranzo A, Milara X, et al. Roflumilast, a
phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
Br J Pharmacol. 2009;156(3):534-544.
https://doi.org/10.1111/j.1476-5381.2008.00041.x
15. Buenestado A, Grassin-Delyle S, Guitard F, et al. Roflumilast
inhibits the release of chemokines and TNF-α from human lung macrophages
stimulated with lipopolysaccharide. Br J Pharmacol.
2012;165(6):1877-1890.
https://doi.org/10.1111/j.1476-5381.2011.01667.x
16. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM. Phosphodiesterase 4B2
is the predominant phosphodiesterase species and undergoes differential
regulation of gene expression in human monocytes and neutrophils. Mol
Pharmacol. 1999;56(1):170-174.
https://doi.org/10.1124/mol.56.1.170
17. Jin SL, Conti M. Induction of the cyclic nucleotide
phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha
responses. Proc Natl Acad Sci U S A. 2002;99(11):7628-7633.
https://doi.org/10.1073/pnas.122041599
18. Zheng XY, Chen JC, Xie QM, Chen JQ, Tang HF. Anti‑inflammatory
effect of ciclamilast in an allergic model involving the expression of
PDE4B. Mol Med Rep. 2019;19(3):1728-1738.
https://doi.org/10.3892/mmr.2019.9802
19. Souto FO, Alves-Filho JC, Turato WM, et al. Essential role of CCR2
in neutrophil tissue infiltration and multiple organ dysfunction in
sepsis. Am J Respir Crit Care Med. 2011;183(2):234-242.
https://doi.org/10.1164/rccm.201003-0416OC
20. Totani L, Amore C, Di Santo A, et al. Roflumilast inhibits
leukocyte–platelet interactions and prevents the prothrombotic
functions of polymorphonuclear leukocytes and monocytes. J Thromb
Haemost. 2016;14(1):191-204.
https://doi.org/https://doi.org/10.1111/jth.13173